| Filed On | Filing |
|---|---|
| 05 Nov 2026 | SCHEDULE 13G/A |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Additional analyses from the Phase 2a induction period for OD-001 further strengthen clinical proof of concept in ulcerative colitis |
| 20 Oct 2026 |
8-K: Regulation FD Disclosure
Forward-looking statements and third-party information This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other... |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In... |
| 06 Aug 2026 | 10-Q |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Data from the Phase 2a monotherapy trial of OD-001 accepted for oral presentation at United European Gastroenterology Week in October |
| 23 Jun 2026 |
8-K: Regulation FD Disclosure
Confidential information, forward-looking statements, and third-party information This presentation (including any discussion that accompanies this presentation) contains highly confidential information regarding Odyssey Therapeutics, In... |
| 17 Jun 2026 | 10-Q |
| 17 Jun 2026 |
8-K: Results of Operations and Financial Condition
Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis |
| 05 Jun 2026 | SCHEDULE 13G |
| 18 May 2026 | SCHEDULE 13G |
| 18 May 2026 | SCHEDULE 13D |
| 18 May 2026 | SCHEDULE 13D |
| 15 May 2026 | SCHEDULE 13D |
| 15 May 2026 | SCHEDULE 13D |
| 13 May 2026 |
Form 4: Tpg Gp A, Llc, Former 10% Owner and 2 others
Acquired 423,111 shares (Other Transaction) · Disposed of 2,351 shares (Other Transaction) ($42.3K) · Received 1,880,497 shares by conversion · 2 more |
| 12 May 2026 |
Form 4: Dimension Capital II, L.p., Director
Received 1,709,543 shares by conversion · Bought 1,111,111 shares ($20M) |
| 12 May 2026 |
Form 3: Dimension Capital II, L.p., Director
Holds 512,862 shares of Common Stock |
| 11 May 2026 |
Form 4: Sr One Capital MANAGEMENT, Llc, 10% owner and 1 other
Received 2,921,061 shares by conversion · Received 320,047 shares by exercise · Sold 1,780 shares ($32K) · 1 more |
Loading...